$TRAX News

Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90

First Tracks Biotherapeutics Announces $200 Million Private Placement

First Tracks Biotherapeutics Announces ~$200M Private Placement Of 6,106,870 Shares At $32.75/Share To Institutional Investors

First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor

Canaccord Genuity Maintains Buy on First Tracks, Raises Price Target to $60

Evercore ISI Group Maintains Outperform on First Tracks, Raises Price Target to $70

7 Reasons First Tracks Biotherapeutics (TRAX) Looks Pricey Following ANB033 Trial Data

First Tracks Biotherapeutics (TRAX) Stock Looks Rich Following Phase 1b Celiac Data

Wells Fargo Maintains Overweight on First Tracks, Raises Price Target to $70

First Tracks Biotherapeutics (TRAX) Reports Positive Phase 1b Cohort 1 Results

First Tracks: ANB033 Delivers, But Cohort 2 Must Follow Through

First Tracks climbs on ‘impressive’ celiac study data

First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals

First Tracks Biotherapeutics Shares Jump 20% After Positive Phase 1b Celiac Disease Trial Results

Why Is First Tracks Biotherapeutics Stock Soaring Monday?

First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

First Tracks Biotherapeutics' ANB033 Demonstrates Statistically Significant Histologic And Symptom Benefits In Phase 1b Celiac Disease Trial

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

Canaccord Genuity Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $50

Evercore ISI Group Initiates Coverage On First Tracks with Outperform Rating, Announces Price Target of $65